Passey: Potenzial Forum: Community User: Passey

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) https://www.marketbeat.com/instant-alerts/atara-biotherapeutics-nasdaqatra-issues-quarterly-earnings-results-beats-estimates-by-051-eps-2025-11-12/

https://www.benzinga.com/markets/equities/25/11/48856735/why-is-cidara-therapeutics-cdtx-stock-trending-overnight?utm_source=TechInvestorNews&utm_campaign=partner_feed&utm_medium=partner_feed&utm_content=site

Guter Tipp gewesen mal wieder, @Orb101, ging gut hoch jetzt.

Bei Zero leider nicht im Angebot, aber sehr interessant: Dexterra Group Aktie ISIN: CA2523711091 Preisziel 13,90, quartalsweise Dividende überlege, über die Hausbank reinzugehen. Informationen Dexterra Group, Inc. engages in the provision of industrial, commercial, and residential products and services. It operates through the Facilities Management, and Workforce Accommodation and Forestry. The Facilities Management segment includes activities relating to the operation and maintenance of property, buildings and infrastructure. The Workforce Accommodation and Forestry segment involves the supply of camp equipment and related operational services to companies whose employees are staying away from home at or near remote worksites. The company was founded on May 16, 1967 and is headquartered in Calgary, Canada.

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Clearmind Medicine

Bin übrigens bei 44 Cent rein, STOPOrder liegt jenseits der Euro-Marke, also definitiv wird es mit Gewinn ausgehen, wenns kracht. DAS allerdings glaube ich noch nicht wirklich. ONDAS ist heute auch wieder gestiegen.